Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]
WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.